WHO ICTRP trial
Factors influencing the outcome of nilotinib treatment in patients with chronic…
NL-OMON41699 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON41699 |
|---|---|
| Public title | Factors influencing the outcome of nilotinib treatment in patients with chronic myeloid leukemia in daily practice |
| Scientific title | Factors influencing the outcome of nilotinib treatment in patients with chronic myeloid leukemia in daily practice - Response and Adherence to Nilotinib in Daily practice (RAND-study) |
| Primary sponsor | Vrije Universiteit Medisch Centrum |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Observational invasive |
| Countries | The Netherlands |
| Conditions | Chronic Myelogenous Leukemia; Cancer of white blood cells;10024324;10024324;Chronic Myelogenous Leukemia; Cancer of white blood cells |
| Interventions | ;Medication Adherence;Nilotinib;Patients experiences;Treatment outcome |
| Registration date | Jul 29, 2015 |
| Target size | 70 |
| Secondary IDs | NL41762.029.13 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: